<DOC>
	<DOCNO>NCT03025282</DOCNO>
	<brief_summary>This exploratory , single-centre , investigator blind , randomize , control , intra-individual study , involve subject psoriasis vulgaris . The objective evaluate , modify Dumas-Scholtz psoriasis mini-zone test , safety efficacy CD10367 solution 1 % 3 % 3-week treatment period daily application .</brief_summary>
	<brief_title>Safety Efficacy CD10367 Psoriasis Vulgaris</brief_title>
	<detailed_description>Study drug apply subject daily , 5 day week first 2 week 4 day third week 6 mini-zones locate least 2 psoriatic plaque describe : - 2 mini-zones pretreated keratolytic product , test : - CD10367 3 % solution - CD10367 solution placebo - 4 mini-zones non-pretreated , test : - CD10367 3 % solution - CD10367 1 % solution - CD10367 solution placebo - Betneval 0.1 % ointment</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>1 . Adult male female age least 18 70 year old inclusive screening visit . 2 . Female non childbearing potential ( postmenopausal [ absence menstrual bleeding 1 year prior screening , without medical reason ] , hysterectomy bilateral oophorectomy ) . 3 . Subject skin phototype I IV Fitzpatrick 's scale . ( Screening visit ) . 4 . The subject clinical diagnosis stable plaque psoriasis , define flare month Screening visit change Screening visit Baseline visit , mild moderate severity . ( Screening visit Baseline Visit ) . 5 . The subject present least six eligible minizones , least two psoriasis plaque ( Screening visit verify also Baseline Visit ) specific severity grade , 6 . Subject agree wear his/her contact lenses Baseline visit till D19 visit , ( Screening visit ) 1 . The subject present guttate , erythrodermic , exfoliative , inverse , pustular , palmo plantar , infect ulcerated psoriasis ( Screening visit ) . 2 . The subject uncontrolled serious disease , medical surgical condition , may either interfere interpretation clinical trial result , and/or put subject significant risk ( accord Investigator 's judgment ) he/she participate clinical trial ( e.g . history ongoing gastric duodenal ulcer , clinically significant lung disease , etc . ) ( Screening visit ) . 3 . The subject know suspected allergy sensitivities component study drug keratolytic product ( see Investigator 's Brochure/Product label ) . ( Screening visit ) . 4 . The subject known history adverse drug reaction hypersensitivity product mode action 5 . The subject abnormal clinically significant finding accord ophthalmologist , ophthalmological exam Screening visit , 6 . The subject present abnormal laboratory test judge clinically significant investigator ( blood sampling urinalysis do Screening visit ) , 7 . The subject QTc interval &gt; 450msec abnormal ECG value consider clinically significant cardiologist ( Screening visit ) . 8 . The subject receive , apply take specified treatment within specified time frame prior Baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>